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Abstract In athletes, a secure diagnosis of exercise-in-
duced bronchoconstriction (EIB) is dependent on objective
testing. Evaluating spirometric indices of airflow before
and following an exercise bout is intuitively the optimal
means for the diagnosis; however, this approach is recog-
nized as having several key limitations. Accordingly,
alternative indirect bronchoprovocation tests have been
recommended as surrogate means for obtaining a diagnosis
of EIB. Of these tests, it is often argued that the eucapnic
voluntary hyperpnea (EVH) challenge represents the ‘gold
standard’. This article provides a state-of-the-art review of
EVH, including an overview of the test methodology and
its interpretation. We also address the performance of EVH
against the other functional and clinical approaches
commonly adopted for the diagnosis of EIB. The published
evidence supports a key role for EVH in the diagnostic
algorithm for EIB testing in athletes. However, its wide
sensitivity and specificity and poor repeatability preclude
EVH from being termed a ‘gold standard’ test for EIB.
Key Points
Despite the long history and widespread use of the
eucapnic voluntary hyperpnea (EVH) test in clinical
practice, data to support its position as the ‘gold
standard’ in the diagnosis of exercise-induced
bronchoconstriction (EIB) in athletes are scarce.
The EVH test demonstrates poor test–retest
reliability in athletes with mild EIB, and the
implications for performance or health in an athlete
with a 10–15 % fall in forced expiratory volume in
1 s following EVH still require elucidation.
The EVH test has a key role in diagnosing EIB in
athletes but should not be termed the ‘gold standard’.
1 Introduction
Exercise-induced bronchoconstriction (EIB) describes the
phenomenon of transient reversible narrowing of the air-
ways that occurs in association with exercise [1, 2]. The
condition is highly prevalent in athletes, and establishing
the diagnosis is important, given its potential impact on
both health and performance [3, 4].
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Research has consistently revealed a poor relationship
between the presence of ‘asthma-type’ symptoms and
objective evidence of EIB in athletes [5–8]. Furthermore,
resting spirometric values are poorly predictive of EIB in
this population [9]. Thus, to secure a diagnosis of EIB, it is
important to perform objective testing to confirm any
reversible change in airway function [10].
When an athlete’s history is suggestive of EIB, mea-
suring the change in forced expiratory volume in 1 s
(FEV1), before and following an exercise challenge test
(ECT), represents the most intuitive method for diagnosis
[1, 10, 11]. Indeed, since the 1970s, investigations have
been conducted to standardize ECT procedures and inter-
pretation of their results [12]. However, difficulties with
‘field’ exercise settings—specifically, inability to easily
control ambient conditions and the challenge intensity—
inherently limit the application of this approach [13]. Thus,
whilst field-testing may be specific, it has poor diagnostic
sensitivity for detecting EIB [14]. On the other hand,
standardized laboratory exercise challenges may fail to
properly reproduce the bronchoprovocative stimulus
experienced by athletes when practicing in their own
sporting discipline [15]. Moreover, minor alterations in
exercise load and intensity can impact significantly on the
prevalence of EIB [16].
Accordingly, a number of alternative or surrogate tests
for diagnosing EIB have been proposed. These include
indirect bronchoprovocation tests, which act to replicate
the provocative airway stimulus induced by exercise and
thus precipitate activation of the inflammatory cascade,
causing airway smooth muscle contraction in susceptible
individuals.
One particular indirect bronchoprovocation challenge,
the eucapnic voluntary hyperpnea (EVH) test, has gained
prominence in the diagnosis of EIB and it has long been
recognized that hyperpnea of dry air provides a provocative
stimulus to the airway [17–19].
The EVH test requires an athlete to complete a period of
voluntary hyperpnea with a dry gas inhalant, which desic-
cates the airways, mimicking the osmotic priming stimulus
to EIB [20]. The EVHmethodology was established in 1984
to test army recruits for EIB [21] and has now been employed
for the diagnosis of EIB in athletes for over 25 years [22].
Since the introduction of the EVH, its status as a precise
and reliable test for the diagnosis of EIB in athletes has
risen [23, 24]. Indeed, it is now often considered or cited as
the ‘optimal’ means for establishing the diagnosis of EIB in
athletes [25, 26]. Moreover, it is now frequently employed
to ‘screen’ athletes for airway dysfunction [24, 27], as an
inclusion criterion for studies [28], and to establish the
efficacy of treatment interventions [29].
The aim of this article is to provide a state-of-the-art
review of the place of EVH in testing athletic individuals
for EIB. The review details EVH methodology and
addresses key characteristics of EVH performance against
other commonly utilized functional and clinical approaches
in the diagnosis of EIB, as well as the influence on the
response to the test of pharmacological and non-pharma-
cological interventions. The overall objective is to address
the question, ‘does EVH really deserve to be considered a
‘gold-standard’ test in the diagnostic algorithm for EIB in
athletes?’.
To achieve this aim, electronic searches were under-
taken in the MEDLINE, ISI Web of Science, and The
Cochrane Library databases. The registers were searched
using the terms ‘eucapnic voluntary hyperpnea’, ‘eucap-
nic voluntary hyperpnoea’, ‘eucapnic voluntary hyper-
ventilation’, and ‘EVH’ from the date of inception to
July 2015. The search strategy yielded 612 articles
(PubMed 200, ISI Web of Science 359, The Cochrane
Library 53). Following the removal of duplicates, two
independent reviewers selected papers of potential
interest on the basis of titles and abstracts for a full-text
assessment. Furthermore, reference lists of included
studies, recent reviews, and textbooks were hand sear-
ched for relevant citations. This search resulted in 61
manuscripts that were considered relevant for the aim of
this review.
2 Background
Early work evaluating the clinical utility of hyperpnea as
an airway challenge revealed the importance of maintain-
ing isocapnia during the period of forced hyperpnea. This is
important to avoid the deleterious clinical effects of sys-
temic hypocarbia, but also given the fact that hypocapnia
can promote bronchoconstriction [30].
The utility and clinical application of eucapnic hyperp-
nea was also initially limited by a belief that the cold air
component of the stimulus was important and that contin-
uous monitoring of end-tidal CO2 was required. Subse-
quently, Phillips et al. [31] demonstrated that the
temperature of the air was less important and that a
eucapnic balance could be maintained by admixing
approximately 5 % CO2 in the inspirate. Eliasson et al. [22]
also reported no difference in response between cold and
dry air challenges.
In the 1980s, work in the Walter Reed Military Hospital,
Washington, USA, led to the development of the modern-
day protocol for EVH testing, which is most commonly
utilized in athletes [20, 32].
J. H. Hull et al.
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3 Eucapnic Voluntary Hyperpnea (EVH): Test
Methodology
Prior to undertaking an EVH challenge, subjects are
required to adhere to the recommendations described in
international guidelines for bronchoprovocation testing
[11], including the duration for withholding inhaled asthma
therapy (Fig. 1).
Subjects should be tested only when clinically well
(i.e., free from a respiratory tract infection 6 weeks prior
to the test) [33], should be advised not to ingest caffeine
[34], and should not exercise on the day of the challenge,
as this may exert a refractory protective effect against
EIB [35].
Two types of EVH challenge methodology have been
described: the single-stage and the stepped protocol
(Fig. 1). The single-stage protocol is most commonly
employed for athletes and requires subjects to maintain
minute ventilation (VE) close to 85 % of their maximal
voluntary ventilation (MVV) for 6 min [32]. The target
ventilation is typically predicted by multiplying baseline
FEV1 by 30 or 35 [36], although it is important to note that
this approach is likely to be imprecise in elite athletes [37].
Thus, alternatively, target ventilation can be calculated
from ventilation data obtained in a prior maximal aerobic
exercise test [38].
During the challenge, it is crucial that participants
achieve high (i.e., close to target) ventilation. Previous
research has in fact demonstrated that halving the venti-
lation (e.g., only 15 9 FEV1) and doubling the EVH
challenge time resulted in a 60 % reduction in positive
EVH challenge rate [32]. This has been reported to be
because the small airways are excluded from the condi-
tioning process, and hence the osmotic stimulus for bron-
choconstriction is avoided [20]. Data from large cohorts of
athletes and indeed clinical patients undertaking an EVH
challenge actually suggest that while achieving a ventila-
tion rate above 60 % of MVV (i.e., level that a test is
Stepped protocol
Recommended in paents with severe
or uncontrolled airway disease
Stage 1 Three minutes at 30% MVV 
Spirometry at 1, 5, 10, 15 and 20 minutes or unl stable
Stage 2 Three minutes at 60% MVV
Spirometry at 1, 5, 10, 15 and 20 minutes or unl stable
Stage 3 Three minutes at 90% MVV
Spirometry at 1, 5, 10, 15 and 20 minutes or unl stable
If a fall  in FEV1 ≥ 10% from baseline occurs, the challenge 
is stopped and considered as posive
Single-stepped protocol
Recommended in paents with mild
or controlled airway disease
Stage 1 Six minutes at 85% MVV 
Spirometry at 1, 5, 10, 15 and 20 minutes or unl stable
A posive challenge test is calculated as a fall in FEV1 ≥10% 
from baseline
Measure baseline maximal lung funcon
(MVV is usually calculated from baseline FEV1 x 30 or 35)
EVH challenge
Medicaon
Minimum me from
last dose to challenge
Short acng beta 2 agonist 8 hours
Long acng beta 2 agonist 48 hours
Inhaled corcosteroids No evidence1
Leukotriene modiﬁers 24 hours
Sodium cromoglycate 8 hours
Nedocromil 48 hours
Ipratropium bromide 24 hours
Anhistamines 72 hours
Tiotropium bromide 7 days
1Inhaled corcosteroids may need to be withheld depending on the speciﬁc case, but avoidance is not rounely recommended
Fig. 1 Eucapnic voluntary hyperpnea protocol and test recommendations. EVH eucapnic voluntary hyperpnea, FEV1 forced expiratory volume
in 1 s, MVV maximum voluntary ventilation
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considered valid) is physically challenging, it is readily
achievable in most subjects [23, 39].
For a subject to achieve this target ventilation and
simultaneously maintain eucapnia (i.e., perform hyperp-
nea), the compressed gas source should contain 21 % O2,
5 % CO2, with a balance of N2 (in the UK supplied as BOC
code 280890 AK-PC). This inspirate can be administered
from a gas cylinder via a direct demand valve or a Douglas
bag/balloon (Fig. 2) or via a commercial system, which can
be used to mix O2 and CO2 gases (EucapSys SMTEC,
Switzerland). A video on how to perform an EVH chal-
lenge is available as online Electronic Supplementary
Material (ESM) video S1.
Maximal flow volume loops are recorded at baseline and
at several time points following the challenge [22, 39, 40]
according to international guidelines for standardization of
spirometry [41]. The greatest drop in FEV1 post EVH
challenge (calculated as [pre - post FEV1]/[pre
FEV1] 9 100) is usually seen between 5 and 10 min post
challenge [42].
Some authors have raised concerns regarding a possible
clinical risk of EVH, in terms of its potential to precipitate
a significant reduction in lung function [43]. However, our
group has performed over 1000 EVH tests in athletes of a
variety of disciplines, ages, and EIB severity (unpublished
observations) without seeing any major adverse event such
as a requirement for resuscitation, oxygen therapy, or
hospitalization. Moreover, the EVH test has been reported
to be well tolerated, even in a general population [44].
However, while acknowledging this, it has been proposed
that the stepped protocol may be preferentially selected in
individuals deemed to be potentially more susceptible to
severe bronchoconstriction [32].
4 Interpretation of the EVH Test
An EVH test is typically considered positive if the FEV1
falls C10 % from the baseline measurement within 20 min
of challenge cessation [16, 28]. Indeed, some researchers
have suggested that the C10 % FEV1 fall from baseline
should be seen at consecutive time points post EVH and
that the highest value out of two reproducible measure-
ments (i.e., values within 150 ml or 5 % of each other)
should be selected [1, 45]. Whilst this does support the
physiological nature of a response, there are no robust data
indicating that this criterion improves the sensitivity and/or
specificity of the test.
The diagnostic threshold of a 10 % fall in FEV1 was
initially derived from a study conducted in 90 asthmatic
army recruits [41]. In this trial, a drop of 14 % was 100 %
specific for asthma, but had a sensitivity of only 53 %. A
threshold of 10 % was therefore recommended on the basis
of an improved relationship between specificity and sen-
sitivity (90 and 63 %, respectively). This value also aligns
with the cut-off commonly employed in exercise studies
Douglas bag 150L 
capacity
Gas bottle with 
compressed gas 
mixture:
21% O2
5% CO2
74% N2
Rotameter
Nose clip
Dry gas meter
Stop clock
One way valve
Mouthpiece
High pressure 
tubing
Metal connector
Tubing: 
minimum 
diameter of 3cm
Regulator and demand 
resuscitator 30-150 L/min
Fig. 2 Photograph depicting
the eucapnic voluntary
hyperpnea challenge set-up
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[11]. An analysis of 860 athletes in 12 studies (Table 1)
presents a mean drop of approximately 9 %, which is close
to the current diagnostic threshold. However, the wide
standard deviation (8.4 %) suggests that a lower threshold
may be more appropriate. Indeed, whilst the ‘normative’
response to exercise is mild bronchodilation [46], it is our
experience that the opposite is true following exposure to
EVH.
The fall in FEV1 during a bronchoprovocation challenge
is dependent on the level of ventilation maintained during
the test [20, 32, 47]. In light of this, it is important to report
the VE achieved during the test (Fig. 3). It has been pro-
posed that the severity of bronchoconstriction following an
EVH test can be classified as mild (C10 to B20 %),
moderate (C20 to B30 %), or severe ([30 %), depending
on the magnitude of the largest drop in FEV1 and venti-
lation achieved [20].
The EVH test appears to have good test–retest repro-
ducibility when a subject develops airway narrowing of at
least moderate severity (i.e.,[20 %) [48, 49]; however, it
appears to demonstrate poor repeatability at levels
approximating a mild fall in FEV1 (i.e., 10–15 %). Indeed,
in a recent study by Price et al. [50], the poor diagnostic
repeatability of EVH indicated that, in a cohort of recre-
ational athletes with a mild reduction in FEV1 post EVH,
clinicians should not depend on a single positive test to
support or refute a diagnosis.
The role and value of other surrogate physiological
measures of airflow and bronchoconstriction following
EVH have yet to be established. Indeed FEV1 was found to
be more accurate than forced expiratory flow at 50 %
(FEF50) and, although PEF displayed a similar association,
this parameter is highly effort dependent and thus intrin-
sically less reliable [51]. Other indices of airway dys-
function (i.e., those obtained by impulse oscillometry) have
the potential to provide important information following
EVH [52, 53], yet their contribution in this context remains
to be fully established.
Table 1 Studies reporting use of eucapnic voluntary hyperpnea in athletes
Study Population N Total Negative Positive Achieved
ventilation (l/min)
Predicted
ventilation (%)
Fall in FEV1 % Fall in
FEV1
% Fall in
FEV1
Holzer et al.
[56]
Elite athletes 50 14.2 ± 15.5 50 3.0 ± 2.0 50 25.4 ± 15.0 126.8 ± 21.9 93.8 ± 4.7
Rundell et al.
[14]
Elite winter athletes 38 9.1 ± 6.2 55 4.7 ± 3.2 45 14.5 ± 4.5 104 ± 26 82.6 ± 16
Dickinson
et al. [27]
Winter athletes 14 13.6 ± 8.7 36 5.1 ± 2.5 64 17.0 ± 7.0 NR NR
Parsons et al.
[75]
College athletes 107 6.2 ± 2.6 61 4.2 ± 0.3 39 9.2 ± 0.1 NR NR
Pedersen
et al. [76]
Female swimmers 16 9.2 ± 7.9 67 5.2 ± 3.1 33 18.0 ± 8.4 NR 70.4 ± 13.0
Parsons et al.
[77]
Non-asthmatic athletes 96 5.9 ± 4.3 82 NA 18 NA NR NR
Castricum
et al. [73]
Elite athletes 33 13.2 ± 11.8 52 5.2 ± 2.7 48 21.6 ± 11.9 NR EIB?: 78 ± 11
EIB-: 75 ± 9
Dickinson
et al. [23]
Elite athletes 228 9.3 ± 9.8 66 4.6 ± 2.9 34 18.3 ± 11.9 NR EIB?: 79.1 ± 11.2
EIB-: 79.5 ± 9.8
Ansley et al.
[5]
Professional football
players
65 14.0 ± 11.2 49 6.1 ± 2.8 51 21.5 ± 11.0 NR EIB?: 74.7 ± 6.3
EIB-: 68.3 ± 10.1
Bolger et al.
[78]
Summer sport female
athletes
28 10.91 ± 7.15 64 5.8 ± 0.7 36 20.1 ± 2.5 NR NR
Koch et al.
[79]
Experienced male cyclists
and triathletes
49 11.0 ± 9.0 71 8.0 ± 3.0 29 19.0 ± 14.0 NR NR
Molphy et al.
[39]
Recreational athletes 136 7.4 ± 6.7 87 5.4 ± 2.8 13 19.9 ± 9.7 NR NR
Total 860 9.2 ± 8.4 67 5.1 ± 2.5 33 18.0 ± 9.8
Data are presented as mean ± standard deviation unless otherwise noted
EIB exercise-induced bronchoconstriction, EIB? athletes with a positive EVH result, EIB– athletes with a negative EVH result, EVH eucapnic
voluntary hyperpnea, FEV1 forced expiratory volume in 1 s, NA not applicable, NR not reported
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5 Comparison of EVH with Other Diagnostic
Assessments
A key determinant of whether EVH deserves to be termed a
diagnostic ‘gold standard’ centers on whether it measures
and detects the condition of interest, i.e., does it reliably
diagnose EIB? To evaluate this, it is important to consider
how the diagnosis of EIB is best established and thereafter
how EVH compares with other diagnostic assessment
tools.
In medical practice, the performance of a diagnostic test
is usually considered against an approach based on clinical
assessment, i.e., via history and examination. This clinical
assessment would typically focus on the detection of
symptoms such as exercise-associated cough, wheeze, and
breathlessness. However, in athletic individuals, the stan-
dard clinical diagnostic approach to assessment has been
proven unreliable. This disconnect between symptom per-
ception and bronchospasm is highlighted in recent studies
[54, 55], including the work by Simpson et al. [55] that
describes how athletes continued to report multiple symp-
toms despite successful attenuation of airway narrowing
with beta-2 agonist treatment.
Thus, as might be expected, a great number of studies
have highlighted a poor predictive value of respiratory
symptoms for diagnosing EIB. Holzer et al. [56] studied 50
elite summer-sport athletes: of the 42 subjects reporting
one or more asthma symptoms, only 25 had a positive EVH
challenge result. The symptoms with the greatest positive
predictive value for the EVH challenge were wheeze
without a cold, night awaking with chest tightness, and
exercise-associated dyspnea. Similarly, Dickinson et al.
[23] evaluated 228 British athletes and showed that, among
the 30 athletes reporting a history of asthma, nine (almost
one-third), were EVH negative. In those with a positive
response to EVH (n = 78; 34 %), only 21 had a previous
‘clinical’ diagnosis of EIB. Ansley et al. [5] demonstrated
similar findings in professional football players. In fact, of
the 65 players assessed, clinical symptoms during exercise
were reported by 57 (88 %) athletes, despite only 20 of 42
having a positive EVH response.
The EVH challenge has also been assessed against
alternative objective tests utilized in the diagnosis of EIB.
It is intuitive to compare the test with an exercise chal-
lenge, and this was comprehensively reviewed by Stickland
et al. [57]. Their systematic analysis of EVH versus ECT
included seven prospective cross-sectional trials. The
number of participants in each study ranged from 10 to 33
subjects. Four studies were clearly performed in elite ath-
letes, whilst three did not report the level of fitness or
sports participation.
From a combined total of 138 participants studied, 42
(30 %) tested positive for EIB with the ECT and 74 (54 %)
tested positive with the EVH. However, overall EVH
sensitivity and specificity were extremely variable, with
values ranging from 25 to 90 % and from 0 to 71 %,
respectively. In studies enrolling only athletes, ranges of
sensitivity and specificity only narrowed marginally from
25 to 88 % and from 0 to 67 %, respectively. Using a
different diagnostic threshold for a positive result, the
sensitivity improved at a FEV1 % fall C15 %, yet con-
siderable variability remained among the studies.
The authors concluded that methodological issues, such
as EVH protocols employed and populations studied, lim-
ited the interpretation and generalizability of results. They
also raised concerns regarding a significant risk of spec-
trum bias, i.e., potential for the performance of a diagnostic
test to vary in different clinical settings because each set-
ting has a different representation of subjects.
Sue-Chu et al. [58] compared airway hyper-respon-
siveness (AHR) to methacholine, EVH, exercise, adenosine
50-monophosphate (AMP), and mannitol in 58 cross-
country skiers. Bronchial hyper-responsiveness was
detected in 23 subjects to methacholine (39.6 %), in five
subjects to AMP (8.3 %), and in three subjects to mannitol
(5.1 %). A total of 25 (43 %) subjects were hyper-re-
sponsive to at least one of these stimuli. Of the 33 athletes
tested, three (9 %) and six (18 %) were hyper-responsive
to EVH and field exercise tests, respectively. In those with
a negative methacholine challenge, bronchial reactivity to
either stimulus was detected in four subjects, while no
subject was positive to both tests. On the other hand, of the
14 (42 %) skiers with methacholine hyper-responsiveness,
three were hyper responsive to either test and one to both
tests.
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Fig. 3 Degree of bronchoconstriction after a eucapnic voluntary
hyperpnea challenge in relation to the FEV1 % fall compared with
baseline and the ventilation rate maintained during the test FEV1
forced expiratory volume in 1 s, VE minute ventilation
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The sensitivity of a challenge with mannitol to identify
responsiveness to EVH has been assessed in 50 elite
summer sport athletes [59]. A total of 27 subjects were
previously diagnosed with asthma by a doctor, and 21 were
currently under treatment for EIB or asthma; 25 athletes
were positive to EVH, and 26 subjects had a positive
(provoking dose causing a 10 % fall in FEV1 [PD10])
mannitol challenge. Mannitol demonstrated a sensitivity of
96 % and specificity of 92 % to identify a positive
response to EVH, prompting the authors to suggest man-
nitol as a valid alternative to identify EIB.
More recently, 24 summer-sports athletes who reported
respiratory symptoms on exertion performed a standard
EVH and a mannitol challenge on separate days [60]. Of
these, 11 (46 %) showed a sustained C10 % FEV1 fall after
EVH, while eight (33 %) were positive (15 % FEV1 fall) to
mannitol. A strong association was found between the two
tests (r = 0.7, P\ 0.001).
Finally, Osthoff et al. [61] assessed the feasibility of an
EVH challenge against mannitol to detect AHR in elite
athletes with disability. Among the 44 athletes studied,
nine (20 %) were positive to EVH, and eight (18 %) were
positive to mannitol (PD10); 14 (23 %) subjects were
positive to at least one challenge, and only three athletes
were positive to both. The EVH test showed better positive
and negative predictive values to detect physician-diag-
nosed asthma compared with mannitol (89 and 91 % vs. 75
and 86 %, respectively).
Overall, therefore, it is apparent from these findings that
there can exist significant discrepancies between the
response to an EVH test and clinical symptoms, as well as
the results of different ‘provocation’ challenges.
6 Influence of Pharmacological and Non-
Pharmacological Interventions on EVH
Response
The EVH test is also often employed to objectively eval-
uate airway response to a therapeutic intervention. A single
dose of terbutaline (0.5 mg) has been shown to offer sig-
nificant protection against hyperpnea-induced bron-
choconstriction [62]. Moreover, Kippelen et al. [63]
reported that a single high dose of beclomethasone dipro-
pionate significantly inhibited bronchoconstriction after
EVH in both untrained subjects and athletes with EIB. The
same group showed a significant bronchoprotective effect
against EVH with sodium cromoglycate [64]. In a ran-
domized, double-blind, placebo-controlled trial performed
in 11 physically active EIB positive subjects, montelukast
provided 44 % protection from EIB after EVH [65].
The impact of non-pharmacological interventions on
EVH response has also been evaluated, particularly in the
context of dietarymodification. Tecklenburg-Lund et al. [66]
showed that a 3-week fish oil supplementation significantly
inhibited hyperpnea-induced bronchoconstriction.
The effect of a patented marine lipid extract (PCSO-
524) was more recently assessed in a double-blind ran-
domized controlled trial (RCT) performed in 20 subjects
with asthma [67]. Results obtained showed that the PCSO-
524 diet significantly reduced the maximum FEV1 fall post
EVH compared with usual and placebo diet.
In a double-blind, placebo-controlled RCT in 18 EIB-
positive subjects, the post-EVH bronchoconstriction was
significantly attenuated after 4 and 8 weeks of supple-
mentation with whey proteins [68].
7 Discussion
7.1 Is EVH Truly a ‘Gold Standard’
for the Diagnosis of Exercise-Induced
Bronchoconstriction?
The term ‘gold standard’ is generally taken to represent the
‘paradigm’ of absolute correctness and the best standard in
the field against which to compare the characteristics of a
novel diagnostic procedure or method [69].
The EVH test has been cited as optimal or the ‘gold
standard’ and employed in clinical practice to provide a
definitive diagnosis of EIB in athletes presenting with
respiratory symptoms [3]. As such, it has been endorsed
by the International Olympic Committee as the airway
challenge of choice in the diagnosis of EIB in athletes
[20].
Our review has highlighted that, despite the long his-
tory and widespread use of EVH, data to support its
position as the ‘gold standard’ are sparse. Indeed, within
the limited dataset available, the data are highly hetero-
geneous with regards to athletes’ age, sex, sporting dis-
cipline, and level of physical activity. In addition, there
are significant methodological differences concerning the
clinical (EIB with or without asthma) and functional
(FEV1 % fall) adopted diagnostic criteria, the length of
the challenge, and the ventilation rate, to permit a
definitive conclusion.
The comprehensive systematic review comparing EVH
with ECT performed by Stickland et al. [57] indicates that
even the best studies reveal a variance in specificity and
sensitivity to a degree that cannot permit the term ‘gold
standard’ to be applied. Similar conclusions can be reached
analyzing studies assessing the role of EVH against other
direct and indirect challenges (e.g., mannitol).
Moreover, in terms of methodology, the EVH test has
important limitations, including the cost of the compressed
gas mixture and a requirement for specialist equipment and
Eucapnic Voluntary Hyperpnea Testing in Athletes
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skilled technicians to conduct the challenge. In this respect,
trained specialists should perform EVH, with precautions
taken to minimize the risk of an adverse event (i.e., severe
bronchoconstriction) [1].
It could be also debated whether EVH represents an
appropriate diagnostic test only in athletes or even in non-
competitive exercisers and sedentary subjects who might
not easily maintain high ventilation rates for a prolonged
time. Indeed, one of the major strengths of EVH testing in
elite athletes is the ability to achieve a VE rate that mimics
the demands of high-intensity exercise. However, when
considered from a recreational or sedentary perspective, the
increased ventilation associated with EVH may not reflect
real life, i.e., EVH may desiccate the airway to a greater
extent than typical exercise in normal subjects.
This observation may be particularly pertinent in the
evaluation of airway symptoms in elite swimmers. In this
specific population of athletes, there exists a high preva-
lence of respiratory symptoms [70], and EVH has been
utilized to characterize heightened AHR [71, 72]. Yet, the
obvious differences that exist between the dry, cold stimuli
of EVH and the humid, moist, warm environment
encountered in the pool are substantiated by comparator
studies indicating a significantly lower prevalence of EIB
from testing performed at the poolside [73].
Despite these limitations in respect to the application of
the term ‘gold standard’, it remains the authors’ opinion
that EVH is a valuable indirect bronchoprovocation test in
the context of testing athletes for EIB. Moreover, we
believe that the key utility of the EVH test lies with the
finding of a negative result, i.e., in terms of the ability to
rule out a diagnosis of EIB. However, it is equally
important that prevalence estimates are accurate and not
over-estimated by the application of overly sensitive
diagnostic test methodologies, i.e., resulting in a false-
positive diagnosis and potential for mistreatment. Never-
theless, it is essential that clinicians continue to utilize and
undertake some form of objective testing to establish a
secure diagnosis of EIB and not to rely on symptomatic
assessment alone.
7.2 Unmet Needs and Future Perspectives
Several questions regarding the use of EVH in athletes
need to be answered by innovative and well-designed
research studies.
First, the ‘standard’ against which to compare the EVH
challenge for the diagnosis of EIB, remains unclear. Whilst
a clinician-based diagnosis is often used in ‘asthma’ stud-
ies, this is clearly not appropriate in studies of EIB in
athletes. It is not appropriate to nominate EVH to be the
‘gold standard’ on the basis that is it most likely to be
positive and thus may be the most sensitive test. The
literature mostly refers to either field or laboratory exercise
challenges; however, study designs are heterogeneous, and
some utilize logical protocols with dry gas as an inhalate,
while others are less well controlled [74]. Very little robust
evidence is available regarding relationships with other
potentially valuable ‘diagnostic’ endpoints, i.e., if the aim
of EIB detection is to facilitate delivery of treatment to
mitigate symptoms (e.g., exercise dyspnea, cough, and
wheeze), then a more logical comparator may actually be
longitudinal therapeutic response. Likewise, if the aim is to
ensure optimal performance, then use of performance
endpoint or surrogate may be more logical. In the future,
alternative surrogates of airway inflammatory patterns
(e.g., periostin levels) may also become relevant com-
parators. Thus, it may be that long-term follow-up and
surveillance of clinical, physiological, and inflammatory
markers is required to determine whether EVH ‘predicts’
response to treatment and whether it is of support to
manage airway health. It may also be appropriate to eval-
uate outcomes in the context of athletic performance [4].
On the other hand, findings relating EVH to direct
bronchoprovocative challenges are likely to be negatively
influenced by the poor predictive value of these procedures
for detecting EIB in athletes. Therefore, to properly assess
the reliability of EVH in diagnosing EIB in athletes and to
evaluate the best standard in this context, appropriate
comparators and endpoints need to be considered and
agreed.
It is unclear whether EVH provides the same reliability,
in terms of sensitivity and specificity, for diagnosing and
distinguishing between EIB with and without underlying
clinical asthma, which according to the most recent inter-
national guidelines should be considered two distinct
phenotypes in view of the different pathophysiologic
mechanisms and inflammatory patterns [10].
There is also a need to re-evaluate and investigate what
is an appropriate ‘cut-off’ value for EVH, as well as to
better standardize the methodology in performing the test.
It is not clear whether a 10 % fall in FEV1 really represents
the most appropriate diagnostic threshold. The EVH test
demonstrates poor test–retest reliability in athletes with
mild EIB, and the implications on performance or health
for an athlete with a 10–15 % fall in FEV1 following EVH
still require elucidation.
8 Conclusion
The EVH test has a key role in the diagnostic algorithm for
EIB testing in athletes. It undoubtedly detects moderate to
severe AHR in susceptible athletes, and its greatest value
appears to lie in its negative predictive value. However, the
wide sensitivity and specificity indices and poor
J. H. Hull et al.
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repeatability in mild to moderate cases preclude EVH
being termed a ‘gold standard’ test for EIB.
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